Fresenius Nod In EU Adds To Crowded Adalimumab Market
Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.
You may also be interested in...
As Fresenius Kabi receives US FDA approval for its Idacio rival to Humira, positive developments are being seen in terms of adding adalimumab biosimilars to local formularies. Meanwhile, in Europe Stada and Alvotech have broadened access to their Hukyndra high-concentration version.
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.